Dennis O’Dowd has almost twenty-five years of business experience in venture financing, operations, and mergers and acquisitions, primarily in the life sciences industry. Mr. O’Dowd was a principal at Ivy Capital Partners Management, LLC, which managed two orthopedic-focused venture funds with over twenty investments. Mr. O’Dowd served as CFO/COO to Ivy Sports Medicine, LLC, an Ivy portfolio company focused on the repair and preservation of the meniscus. While at ISM Mr. O’Dowd secured multiple financing rounds, including a successful partnership with NJEDA, and ultimately led the sale process of the Company to Stryker. Additionally, Mr. O’Dowd served on a number of Boards at Ivy’s portfolio companies, including IvyRehab Network, Inc. (acquired by a private equity fund) and Ivy Sports Medicine. Prior to joining Ivy, Mr. O’Dowd was a principal at Grumman Hill Group, LLC, a generalist private equity fund, and spent two years each at Salomon Smith Barney in the Mergers and Acquisitions group, and at Price Waterhouse, LLP in the Corporate Finance division. Mr. O’Dowd graduated from Princeton University with an A.B. in Economics.

Tony Chen, Ph.D., obtained his BSE in Biomedical Engineering from the University of Pennsylvania and his PhD in Biomedical Engineering from the University of Rochester. He performed his postdoctoral training at the Hospital for Special Surgery in the Department of Biomechanics under the NIH-sponsored Musculoskeletal T32 training grant. Dr. Chen has received research support through the Weill Cornell Clinical & Translational Science Center KL2 Fellowship and is currently the principal investigator on the NIH-funded SBIR phase I grant awarded to AGelity Biomechanics. Dr. Chen is a member of the Orthopedic Research Society (ORS) and the American Society for Testing and Materials (ASTM). His research interests lie in understanding changes in joint contact mechanics after injuries and the ability of repair technologies in restoring normal joint loads. He is interested in translating these findings to develop solutions to improve long term patient outcomes. Currently Dr. Chen consults regularly with the Company and while an Assistant Professor at HSS.

Robert Klein received his BSE in Metallurgical and Materials Engineering from Lehigh University and his MS in Chemical Engineering, Polymer Processing from Steven Institute of Technology. He has 38 years of experience in the orthopedic industry, starting with 8 years of research at the Hospital for Special Surgery, Department of Biomechanics, followed by 29 years of experience in industry working for Howmedica, Stryker (after acquiring Howmedica), and AGelity Biomechanics. His career at Howmedica started with testing for device verification and transitioned to leadership of a combined technology and product development effort resulting in the launch of Simplex SpeedSet Bone Cement. The combined technology and development role included in-depth experience with quality systems and the product development process.  This was followed by leading a technology development effort for 3D printing of titanium and direct compression molding of UHMWPE and utilizing those technologies for development of the Triathlon Tritanium tibial and patellar knee joint replacement products.  He is currently using his experience to bring this product based on novel polymers and 3D printed titanium through the product development process.

John Dichiara is an independent medical device regulatory consultant with over 30 years experience in regulatory and clinical affairs.  He started his career in the medical device industry in research and development and moved into regulatory affairs at Howmedica where he was the Director of Regulatory Affairs and Public Policy.  With the acquisition of Howmedica by Stryker, Mr. Dichiara became Director of Clinical Affairs for Stryker Howmedica Osteonics.  He later joined ReGen Biologics as Senior Vice president of Regulatory, Quality and Clinical Affairs and continued in the same role at Ivy Sports Medicine. Mr. Dichiara has been involved in regulatory strategy and the preparation of numerous premarket regulatory submissions, along with the design and conduct of clinical trials in both the U.S. and internationally.

Tom Smestad is the principal of Smestad & Associates LLC.  Mr. Smestad has over 40 years of experience in the design, development and regulation of medical products. He has over 20 years experience as an independent consultant to medical device companies in the areas of regulatory affairs, quality assurance, product design and development. Mr. Smestad’s experience encompasses product development strategies, compliance auditing, project management and major regulatory filings including 510(k)s and technical files for medical device CE marking. Mr. Smestad held the position of Vice President of Manufacturing at ReGen Biologics from 1996 to 2000 where he was responsible for the development and manufacture of an implantable meniscus replacement.  In 1994, he was recruited to manage the development of XOMA Corporation’s lead compound for treatment of sepsis. From 1977 to 1994, Mr. Smestad held positions of increasing responsibility in project management, product development, quality control and manufacturing at Collagen Corporation. He holds a B.S. degree in chemistry from University of California, Santa Barbara.